Idiopathic Normal Pressure Hydrocephalus (iNPH)
Conditions
Brief summary
This clinical trial aims to explore the effectiveness and safety of gait improvemen of Neuclare, a science medical device, for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH) Through methods such as Timed Up & Go Test (TUG), 10m gait , iNPH grading scale), etc, gait improvement before and after using Neuclare will be evaluated.
Interventions
DEVICENeuclare
It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
Sponsors
Deepsonbio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Adults aged 60 to 90, regardless of gender * Individuals exhibiting gait disturbances along with at least one of the following symptoms: cognitive impairment or urinary incontinence * Evans' index \> 0.3) * When the symptoms in 2) and 3) cannot be fully explained by other neurological or non-neurological diseases * Diagnosis of INPH based on the Investigator's clinical judgement based on criteria as described in the INPH Guidelines
Exclusion criteria
* Patient with pathological lesions in the brain identified by MRI * A person who is confirmed to have organic brain lesions (e.g., cerebral edema, cerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.) on a brain MRI. * Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs) * History of psychiatric disorder other than the inclusion criteria. * A person with a severe history of cancer/tuberculosis * A person who has contact dermatitis or sensitive skin abnormalities * Patients with a high fever of 40 degrees Celsius or higher based on eardrum body temperature * A person whose bleeding is identified due to a common procedure or surgery that may affect vital signs * A person who is unable to perform MRI tests * A person with an allergic reaction to MRI contrast agents such as Definity or Gadovist. * Other cases where the investigator judged that it is difficult to participate in the study * Patient with behavioral and psychological symptoms of dementia (BPSD) that make cooperation in the clinical trial difficult * Patients with severe cognitive impairment, defined as an MMSE score of 17 or below * Patients who have undergone shunt surgery in the past year * Patients with a history of uncontrolled thyroid, liver, or kidney dysfunction * Patients taking medications that affect gait, cognition, or urinary tract function and who have had a change in medication regimen within the past 3 months. * Patients who have undergone a cerebrospinal fluid drainage test within the past 1 month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Time Up & Go Test : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Time Up \& Go Test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of 10m gait : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by 10m gait |
| Change of iNPH grading scale : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by iNPH grading scale. The overall score may reach values between 0 and 12, with higher scores indicating more severe impairment |
| Change of Trail Making Test Black & White Score : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of Trail Making Test Black \& White Score. The higher scores mean a worse outcome. |
| Change of Modified Rankin Scale(mRS) : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Modified Rankin Scale(mRS). Assessment results range from 0-6 points，a higher score means a worse ending |
| Change of Quality of life-AD Score : From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of Quality of life-AD Score. QoL-AD was comprised of 13 individual items, each measured on a 4-point Likert scale (ranging from 1 \[poor\] to 4 \[excellent\]). Overall QoL-AD score was the sum of the scores for the 13 individual items and ranged from 13 to 52, with higher scores indicating a higher health related quality of life. |
| Change of MMSE-II Score : From Baseline to Week 5 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change of MMSE-II Score. The cognitive function evaluation performed by MMSE test. The Total score range of MMSE is 0-30, and the higher score indicates better cognitive functions. |
| Change in glymphatic activity, structure, functional connectivity measured by MRI: From Baseline to Week 1 | Week 1 | Compare with before and after using Neuclare for the treatment of Idiopathic Normal Pressure Hydrocephalus (iNPH) as evaluated by Change in glymphatic activity, structure, functional connectivity measured by MRI |
Countries
South Korea
Contacts
PRINCIPAL_INVESTIGATORJaeho Kim, M.D. Ph.D
Hallym University Dongtan Sacred Heart Hospital
Outcome results
None listed